CN105229159B - 重组多肽生产 - Google Patents

重组多肽生产 Download PDF

Info

Publication number
CN105229159B
CN105229159B CN201480013725.2A CN201480013725A CN105229159B CN 105229159 B CN105229159 B CN 105229159B CN 201480013725 A CN201480013725 A CN 201480013725A CN 105229159 B CN105229159 B CN 105229159B
Authority
CN
China
Prior art keywords
mirna
mir
cell
cells
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480013725.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN105229159A (zh
Inventor
K·施特赖歇尔
J·雅各布斯
R·W·乔甘塔斯三世
L·戈林里斯
K·拉纳德
M·鲍恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of CN105229159A publication Critical patent/CN105229159A/zh
Application granted granted Critical
Publication of CN105229159B publication Critical patent/CN105229159B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201480013725.2A 2013-03-14 2014-03-12 重组多肽生产 Active CN105229159B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361782180P 2013-03-14 2013-03-14
US61/782,180 2013-03-14
PCT/US2014/024512 WO2014159633A1 (en) 2013-03-14 2014-03-12 Recombinant polypeptide production

Publications (2)

Publication Number Publication Date
CN105229159A CN105229159A (zh) 2016-01-06
CN105229159B true CN105229159B (zh) 2021-07-06

Family

ID=51625216

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480013725.2A Active CN105229159B (zh) 2013-03-14 2014-03-12 重组多肽生产

Country Status (8)

Country Link
US (1) US10006026B2 (enExample)
EP (1) EP2971035B1 (enExample)
JP (1) JP6445516B2 (enExample)
CN (1) CN105229159B (enExample)
AU (1) AU2014244588B2 (enExample)
CA (1) CA2902581C (enExample)
ES (1) ES2743506T3 (enExample)
WO (1) WO2014159633A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
EP3240894B1 (en) * 2014-12-23 2021-01-27 University of Georgia Research Foundation RECOMBINANT CELLS COMPRISING miRNA MIMICS
US10383935B2 (en) * 2015-09-23 2019-08-20 Regents Of The University Of Minnesota Methods of making and using live attenuated viruses
CN111148835A (zh) * 2017-10-02 2020-05-12 阿斯利康(瑞典)有限公司 用于增加蛋白产量的细胞系和方法
WO2019227259A1 (zh) * 2018-05-26 2019-12-05 深圳市博奥康生物科技有限公司 一种基于哺乳动物病毒的介导miRNA过表达方法
WO2019227253A1 (zh) * 2018-05-26 2019-12-05 深圳市博奥康生物科技有限公司 miRNA-21过表达载体的构建及其应用
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN117535292B (zh) * 2023-11-01 2025-05-09 新乡医学院 let-7a在CHO细胞重组蛋白表达中的应用、表达系统

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101541972A (zh) * 2006-08-04 2009-09-23 都柏林城市大学 生产重组生物产品的方法
US20100226884A1 (en) * 2009-01-20 2010-09-09 Immunomedics, Inc. Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
WO2010129919A1 (en) * 2009-05-08 2010-11-11 Research Development Foundation Mirna expression in allergic disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632672B2 (en) * 1998-08-19 2003-10-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for genomic modification
EP1833961B1 (en) * 2004-10-15 2011-07-20 Monell Chemical Senses Center Methods for culturing mammalian taste cells
EP2054529B1 (en) 2006-08-25 2014-03-26 Duke University Methods for in vivo identification of endogenous mrna targets of micrornas
US20110098346A1 (en) * 2008-05-19 2011-04-28 Agency For Science, Technology And Research Nucleic acid molecule and method of targeting gene expression to gliomas
EP2326730B1 (en) * 2008-08-19 2014-03-19 Maine Institute For Human Genetics And Health Micro rna (mirna) and neurofibromatosis type 1 : a role in diagnosis and therapy
CN102712904A (zh) * 2009-11-11 2012-10-03 桑福德—伯恩哈姆医学研究协会 用于产生和调节iPS细胞的方法及其组合物
AR093183A1 (es) 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101541972A (zh) * 2006-08-04 2009-09-23 都柏林城市大学 生产重组生物产品的方法
US20100226884A1 (en) * 2009-01-20 2010-09-09 Immunomedics, Inc. Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
WO2010129919A1 (en) * 2009-05-08 2010-11-11 Research Development Foundation Mirna expression in allergic disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
let-7在肿瘤中的研究进展;朱秀明 等;《国际肿瘤学杂志》;20110228;第38卷(第2期);第90页右栏第1段 *
MicroRNAs as targets for engineering of CHO cell factories;Müller D 等;《Trends Biotechnol》;20080528;第26卷(第7期);第359页右栏，表1 *
Specificity and functionality of microRNA inhibitors;Barbara Robertson 等;《Silence》;20100401;第1卷;第2页左栏，图1 *
Stable inhibition of mmu-miR-466h-5p improves apoptosis resistance and protein production in CHO cells;Druz A 等;《Metab Eng》;20130129;第16卷;摘要，第3页第3段、第5页第2节、第6页第5节，图2、6 *
The let-7 family of microRNAs;Roush S 等;《Trends Cell Biol》;20080904;第18卷(第10期);第505-516页 *

Also Published As

Publication number Publication date
AU2014244588A1 (en) 2015-10-01
JP6445516B2 (ja) 2018-12-26
ES2743506T3 (es) 2020-02-19
AU2014244588B2 (en) 2017-11-30
JP2016511005A (ja) 2016-04-14
EP2971035B1 (en) 2019-06-12
WO2014159633A1 (en) 2014-10-02
US20160024502A1 (en) 2016-01-28
HK1220492A1 (en) 2017-05-05
CA2902581A1 (en) 2014-10-02
EP2971035A4 (en) 2016-11-09
HK1218562A1 (zh) 2017-02-24
US10006026B2 (en) 2018-06-26
CN105229159A (zh) 2016-01-06
EP2971035A1 (en) 2016-01-20
CA2902581C (en) 2023-08-08

Similar Documents

Publication Publication Date Title
CN105229159B (zh) 重组多肽生产
EP2937417B1 (en) MiRNAs enhancing cell productivity
EP2859103B1 (en) CELL ENGINEERING USING RNAs
JP2025118760A (ja) 細胞の選択方法
CN105849265B (zh) 用于产生供生产重组蛋白的哺乳动物生产细胞的物品和方法
EP2396404A1 (en) Rnai based selection system
WO2024023746A1 (en) Improved production of cd39 variants
EP4092125A1 (en) Method for producing a biomolecule by a cell
HK1218562B (zh) 重组多肽生产
HK1220492B (en) Recombinant polypeptide production
US12275953B2 (en) Methods for screening host cells expressing target proteins
US20250313878A1 (en) IMPROVED PROTEIN PRODUCTION USING miRNA TECHNOLOGY
Švab et al. High Throughput miRNA Screening Identifies miR-574-3p Hyperproductive Effect in CHO Cells. Biomolecules 2021, 11, 1125
WO2014204405A1 (en) Method for modulating recombinant protein production
Greenlees et al. Inhibition of microRNA-let-7a Increases the Specific Productivity of Antibody-Producing CHO Cell Lines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1218562

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment